ProPhase Labs Statistics
Total Valuation
ProPhase Labs has a market cap or net worth of $2.40 million. The enterprise value is $9.68 million.
Important Dates
The last earnings date was Wednesday, November 19, 2025, before market open.
| Earnings Date | Nov 19, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
ProPhase Labs has 4.62 million shares outstanding. The number of shares has increased by 94.71% in one year.
| Current Share Class | 4.62M |
| Shares Outstanding | 4.62M |
| Shares Change (YoY) | +94.71% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 7.22% |
| Owned by Institutions (%) | 6.56% |
| Float | 4.28M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.37 |
| Forward PS | 0.24 |
| PB Ratio | 0.31 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.92 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.14, with a Debt / Equity ratio of 1.12.
| Current Ratio | 0.14 |
| Quick Ratio | 0.07 |
| Debt / Equity | 1.12 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -7.28 |
Financial Efficiency
Return on equity (ROE) is -220.34% and return on invested capital (ROIC) is -44.99%.
| Return on Equity (ROE) | -220.34% |
| Return on Assets (ROA) | -23.50% |
| Return on Invested Capital (ROIC) | -44.99% |
| Return on Capital Employed (ROCE) | -284.31% |
| Revenue Per Employee | $52,656 |
| Profits Per Employee | -$434,417 |
| Employee Count | 96 |
| Asset Turnover | 0.06 |
| Inventory Turnover | 1.92 |
Taxes
In the past 12 months, ProPhase Labs has paid $15.18 million in taxes.
| Income Tax | 15.18M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -91.75% in the last 52 weeks. The beta is -0.64, so ProPhase Labs's price volatility has been lower than the market average.
| Beta (5Y) | -0.64 |
| 52-Week Price Change | -91.75% |
| 50-Day Moving Average | 2.40 |
| 200-Day Moving Average | 3.44 |
| Relative Strength Index (RSI) | 20.35 |
| Average Volume (20 Days) | 2,662,892 |
Short Selling Information
The latest short interest is 300,239, so 6.50% of the outstanding shares have been sold short.
| Short Interest | 300,239 |
| Short Previous Month | 139,873 |
| Short % of Shares Out | 6.50% |
| Short % of Float | 7.01% |
| Short Ratio (days to cover) | 0.08 |
Income Statement
In the last 12 months, ProPhase Labs had revenue of $5.06 million and -$41.70 million in losses. Loss per share was -$11.64.
| Revenue | 5.06M |
| Gross Profit | 987,000 |
| Operating Income | -29.61M |
| Pretax Income | -34.38M |
| Net Income | -41.70M |
| EBITDA | -24.22M |
| EBIT | -29.61M |
| Loss Per Share | -$11.64 |
Full Income StatementBalance Sheet
The company has $405,000 in cash and $7.68 million in debt, giving a net cash position of -$7.28 million or -$1.58 per share.
| Cash & Cash Equivalents | 405,000 |
| Total Debt | 7.68M |
| Net Cash | -7.28M |
| Net Cash Per Share | -$1.58 |
| Equity (Book Value) | 6.86M |
| Book Value Per Share | 1.65 |
| Working Capital | -47.51M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$10.63 million and capital expenditures -$40,000, giving a free cash flow of -$10.67 million.
| Operating Cash Flow | -10.63M |
| Capital Expenditures | -40,000 |
| Free Cash Flow | -10.67M |
| FCF Per Share | -$2.31 |
Full Cash Flow StatementMargins
| Gross Margin | 19.53% |
| Operating Margin | -585.78% |
| Pretax Margin | -680.20% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ProPhase Labs does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -94.71% |
| Shareholder Yield | -94.71% |
| Earnings Yield | -1,736.72% |
| FCF Yield | -444.42% |
Dividend DetailsAnalyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on December 22, 2025. It was a reverse split with a ratio of 1:10.
| Last Split Date | Dec 22, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
ProPhase Labs has an Altman Z-Score of -3.5 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -3.5 |
| Piotroski F-Score | 1 |
